StockData
AgomAb Therapeutics NV logo

AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.82−0.10 (-1.69%)

Close on Nov 18, 2026Market cap $145.50KP/E –Yield –

AgomAb Therapeutics cash

Cash and short-term investments held at the end of each period.

AgomAb Therapeutics's cash was €86.42M at Dec 31, 2025. For fiscal 2025 it was €86.42M, down 49.6% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025€86.42M-49.6%
FY2024Dec 31, 2024€171.46M+40.1%
FY2023Dec 31, 2023€122.40M+342.4%
FY2022Dec 31, 2022€27.67M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025€86.42M–
Q4 FY2024Dec 31, 2024€171.46M–
Q4 FY2023Dec 31, 2023€122.40M–
Q4 FY2022Dec 31, 2022€27.67M–

More AgomAb Therapeutics figures

See a number that looks wrong?